Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dabrafenib”

141 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 141 results

Testing effectiveness (Phase 2)UnknownNCT03668431
What this trial is testing

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Massachusetts General Hospital 25
Testing effectiveness (Phase 2)Study completedNCT01928940
What this trial is testing

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Who this might be right for
Solid Tumours
GlaxoSmithKline 12
Early research (Phase 1)Ended earlyNCT02200562
What this trial is testing

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

Who this might be right for
Stage III or IV Melanoma
University of Utah 6
Early research (Phase 1)Ended earlyNCT03332589
What this trial is testing

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Who this might be right for
Malignant MelanomaBrain Metastases
Spirita Oncology, LLC 4
Early research (Phase 1)Study completedNCT00880321
What this trial is testing

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 170
Early research (Phase 1)UnknownNCT03088176
What this trial is testing

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Who this might be right for
MelanomaBRAF Gene Mutation
West Cancer Center 4
Early research (Phase 1)Active Not RecruitingNCT01947023
What this trial is testing

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Who this might be right for
Metastatic Thyroid Gland CarcinomaUnresectable Thyroid Gland Carcinoma
National Cancer Institute (NCI) 23
Not applicableNo Longer AvailableNCT04544202
What this trial is testing

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Who this might be right for
MelanomaAdjuvant
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT01231594
What this trial is testing

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Who this might be right for
Cancer
Novartis Pharmaceuticals 214
Testing effectiveness (Phase 2)WithdrawnNCT02672358
What this trial is testing

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT01582997
What this trial is testing

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 12
Testing effectiveness (Phase 2)Study completedNCT02367859
What this trial is testing

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Who this might be right for
AmeloblastomaBRAF Gene Mutation
Stanford University 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT02858921
What this trial is testing

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Who this might be right for
Melanoma
Melanoma Institute Australia 60
Early research (Phase 1)Ended earlyNCT03272464
What this trial is testing

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Who this might be right for
Melanoma
Massachusetts General Hospital 1
Not applicableEnded earlyNCT05848219
What this trial is testing

Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

Who this might be right for
Metastatic Melanoma
Novartis Pharmaceuticals 543
Testing effectiveness (Phase 2)Active Not RecruitingNCT02231775
What this trial is testing

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Who this might be right for
Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7
M.D. Anderson Cancer Center 58
Testing effectiveness (Phase 2)Looking for participantsNCT07110246
What this trial is testing

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Who this might be right for
BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco 96
Testing effectiveness (Phase 2)UnknownNCT06362694
What this trial is testing

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

Who this might be right for
Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia 10
Testing effectiveness (Phase 2)WithdrawnNCT04739566
What this trial is testing

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

Who this might be right for
Thyroid Gland Anaplastic Carcinoma
Saint Petersburg State University, Russia
Not applicableLooking for participantsNCT06262919
What this trial is testing

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Who this might be right for
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals 110
Next Page